Prot #207966: A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks i

Project: Research project

Project Details

StatusActive
Effective start/end date2/7/182/7/21

Funding

  • PPD Investigator Services, LLC (Prot #207966)
  • GlaxoSmithKline LLC (Prot #207966)